Get started
Author

Rinske S. Boersma

Observed names: R. S. Boersma, R.S. Boersma, Rinske Boersma, Rinske S Boersma
Institution: Amphia Ziekenhuis
ORCID: 0000-0003-1713-8666
Observed ORCID: 0000-0003-1713-8666
OpenAlex ID: A5003185931
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study
2020 · Michele Cavo, Francesca Gay, et al. · The Lancet Haematology · 399
PDF
Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies
2007 · R.S. Boersma, K.-S.G. Jie, et al. · Annals of Oncology · 144
Hydrophilic surface coatings with embedded biocidal silver nanoparticles and sodium heparin for central venous catheters
2010 · Kris N.J. Stevens, Sander Croes, et al. · Biomaterials · 107
Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial
2019 · Martine E.D. Chamuleau, Coreline N. Burggraaff, et al. · Haematologica · 58
PDF
Epcoritamab, lenalidomide, and rituximab versus lenalidomide and rituximab for relapsed or refractory follicular lymphoma (EPCORE FL-1): a global, open-label, randomised, phase 3 trial
2025 · Lorenzo Falchi, Marcel Nijland, et al. · The Lancet · 50
Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS
2020 · Gerwin Huls, Dana A. Chitu, et al. · Blood Advances · 34
PDF
Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial
2021 · Anita W. Rijneveld, Bronno van der Holt, et al. · Blood Advances · 26
PDF
Addition of the nuclear export inhibitor selinexor to standard intensive treatment for elderly patients with acute myeloid leukemia and high risk myelodysplastic syndrome
2022 · J. J. W. M. Janssen, B. Löwenberg, et al. · Leukemia · 24
PDF
Clinical practices concerning central venous catheters in haematological patients
2010 · R.S. Boersma, H.C. Schouten · European Journal of Oncology Nursing · 24
Prospective Validation of Circulating Tumor DNA Measurable Residual Disease After First-Line Therapy in Large B-Cell Lymphoma
2025 · Steven Wang, Marcel Nijland, et al. · Journal of Clinical Oncology · 20
Concentrated citrate locking in order to reduce the long-term complications of central venous catheters: a randomized controlled trial in patients with hematological malignancies
2014 · R. S. Boersma, K. S. Jie, et al. · Supportive Care in Cancer · 19
Setting up a national infrastructure for survivorship care after treatment for Hodgkin lymphoma
2019 · Annelies Nijdam, Nicky Dekker, et al. · British Journal of Haematology · 18
CD34+CD38- leukemia stem cells predict clinical outcomes in acute myeloid leukemia patients treated non-intensively with hypomethylating agents
2025 · Tom Reuvekamp, Lok Lam Ngai, et al. · Leukemia · 15
Rituximab-Lenalidomide(R2) Maintenance Is Superior to Rituximab Maintenance after First Line Immunochemotherapy in Mantle Cell Lymphoma: Results of the MCL R2 Elderly Clinical Trial
2021 · Vincent Ribrag, Violaine Safar, et al. · Blood · 14
Distinct peripheral T-cell and NK-cell profiles in HGBL-MYC/BCL2 vs patients with DLBCL NOS
2024 · A. Vera de Jonge, Carolien Duetz, et al. · Blood Advances · 12
Numerous Russell bodies and Dutcher bodies in multiple myeloma
2014 · Adriaan J. van Gammeren, Luthy S. M. Alcala, et al. · British Journal of Haematology · 11
PDF
Congenital Thrombophilia and Central Venous Catheter-Related Thrombosis in Patients With Cancer
2010 · Rinske S. Boersma, Karly Hamulyak, et al. · Clinical and Applied Thrombosis/Hemostasis · 11
PDF
Biomarkers for Prediction of Central Venous Catheter Related-Thrombosis in Patients With Hematological Malignancies
2015 · R. S. Boersma, K. Hamulyak, et al. · Clinical and Applied Thrombosis/Hemostasis · 10
PDF
Induction and Maintenance Therapy in Elderly Patients with Mantle Cell Lymphoma: Double-Randomized MCL R2 Elderly Clinical Trial By the European Mantle Cell Lymphoma Network
2023 · Vincent Ribrag, Violaine Safar, et al. · Blood · 9
A non-randomized risk-adjusted comparison of lenalidomide + R-CHOP versus R-CHOP for MYC-rearranged DLBCL patients
2023 · A. Vera de Jonge, Erik van Werkhoven, et al. · Blood Cancer Journal · 9
PDF
Atezolizumab consolidation in patients with high-risk diffuse large B-cell lymphoma in complete remission after R-CHOP
2025 · Marcel Nijland, Djamila E. Issa, et al. · Blood Advances · 7
PDF
Prospective validation of end of treatment ctDNA-MRD by PhasED-Seq in DLBCL patients from a national trial.
2025 · Steven Wang, Marcel Nijland, et al. · Journal of Clinical Oncology · 6
PDF
Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine
2023 · Jacobien R. Hilberink, Isabelle A. van Zeventer, et al. · Blood Cancer Journal · 5
PDF
Simultaneous bilateral spontaneous pneumothorax as a presenting symptom of osteosarcoma
2007 · R.S. Boersma, J. Buijs · European Journal of Internal Medicine · 5
Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome
2024 · Gerwin Huls, Dana A. Chitu, et al. · Annals of Hematology · 4
PDF
Works count: 39
Citation count: 1,053
H-index: 14
I10-index: 18
Year
Topic
Type